Moderna’s COVID-19 vaccine candidate named mRNA-1273 is deployed on RNA to elicit a durable immune response against the viral infection.
Moderna’s COVID-19 vaccine candidate named mRNA-1273 is deployed on RNA to elicit a durable immune response against the viral infection.Moderna Inc. is a clinical-stage biotechnology company pioneering in messenger RNA (mRNA) to develop therapeutics and vaccines in creating new generations of medicines. The vaccine named mRNA-1273, developed by Moderna partnered with the U.S. National Institute of Allergy, and Infectious Diseases (NIAID), has entered phase 3 of clinical trials. The vaccine is based on deploying a tiny snip of genetic code called messenger Ribonucleic acid (RNA) to trigger the immune response.
According to the interim data provided from phase 1 human trials, the vaccine technology was proved to be well tolerated and had elicited durable immune responses to viral antigens.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.
Copied!